|
[1]
|
Kannan, N. and Neuwald, A.F. (2004) Evolutionary Constraints Associated with Functional Specificity of the CMGC Protein Kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2α. Protein Science, 13, 2059-2077. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Manning, G., Whyte, D.B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The Protein Kinase Complement of the Human Genome. Science, 298, 1912-1934. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Chang, W., Liu, T., Yang, W., Lee, C., Lin, Y., Chen, T., et al. (2011) Amiloride Modulates Alternative Splicing in Leukemic Cells and Resensitizes Bcr-AblT315I Mutant Cells to Imatinib. Cancer Research, 71, 383-392. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Kim, Y.H., Choi, C.Y., Lee, S., Conti, M.A. and Kim, Y. (1998) Homeodomain-Interacting Protein Kinases, a Novel Family of Co-Repressors for Homeodomain Transcription Factors. Journal of Biological Chemistry, 273, 25875-25879. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
van der Laden, J., Soppa, U. and Becker, W. (2015) Effect of Tyrosine Autophosphorylation on Catalytic Activity and Subcellular Localisation of Homeodomain-Interacting Protein Kinases (HIPK). Cell Communication and Signaling, 13, Article No. 3. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Akaike, Y., Kuwano, Y., Nishida, K., Kurokawa, K., Kajita, K., Kano, S., et al. (2014) Homeodomain-Interacting Protein Kinase 2 Regulates DNA Damage Response through Interacting with Heterochromatin Protein 1γ. Oncogene, 34, 3463-3473. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Higashimoto, Y., Saito, S., Tong, X., Hong, A., Sakaguchi, K., Appella, E., et al. (2000) Human P53 Is Phosphorylated on Serines 6 and 9 in Response to DNA Damage-Inducing Agents. Journal of Biological Chemistry, 275, 23199-23203. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Venables, J.P., Bourgeois, C.F., Dalgliesh, C., Kister, L., Stevenin, J. and Elliott, D.J. (2005) Up-Regulation of the Ubiquitous Alternative Splicing Factor Tra2β Causes Inclusion of a Germ Cell-Specific Exon. Human Molecular Genetics, 14, 2289-2303. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Hunter, T. (2000) Signaling—2000 and Beyond. Cell, 100, 113-127. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Ashkenazi, A. and Dixit, V.M. (1998) Death Receptors: Signaling and Modulation. Science, 281, 1305-1308. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Rochat-Steiner, V., Becker, K., Micheau, O., Schneider, P., Burns, K. and Tschopp, J. (2000) Fist/HIPK3: A Fas/FADD-Interacting Serine/Threonine Kinase That Induces FADD Phosphorylation and Inhibits Fas-Mediated Jun NH(2)-Terminal Kinase Activation. The Journal of Experimental Medicine, 192, 1165-1174. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Conte, A. and Pierantoni, G.M. (2018) Update on the Regulation of HIPK1, HIPK2 and HIPK3 Protein Kinases by MicroRNAs. MicroRNA, 7, 178-186. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Pallante, P., Battista, S., Pierantoni, G.M. and Fusco, A. (2013) Deregulation of MicroRNA Expression in Thyroid Neoplasias. Nature Reviews Endocrinology, 10, 88-101. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Mosakhani, N., Räty, R., Tyybäkinoja, A., Karjalainen-Lindsberg, M., Elonen, E. and Knuutila, S. (2013) MicroRNA Profiling in Chemoresistant and Chemosensitive Acute Myeloid Leukemia. Cytogenetic and Genome Research, 141, 272-276. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Chan, J.K., Kiet, T.K., Blansit, K., Ramasubbaiah, R., Hilton, J.F., Kapp, D.S., et al. (2014) miR-378 as a Biomarker for Response to Anti-Angiogenic Treatment in Ovarian Cancer. Gynecologic Oncology, 133, 568-574. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Xu, M., Jin, H., Xu, C., Sun, B., Mao, Z., Bi, W., et al. (2014) miR-382 Inhibits Tumor Growth and Enhance Chemosensitivity in Osteosarcoma. Oncotarget, 5, 9472-9483. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Landais, S., Landry, S., Legault, P. and Rassart, E. (2007) Oncogenic Potential of the miR-106-363 Cluster and Its Implication in Human T-Cell Leukemia. Cancer Research, 67, 5699-5707. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Locke, J.M., da Silva Xavier, G., Dawe, H.R., Rutter, G.A. and Harries, L.W. (2013) Increased Expression of miR-187 in Human Islets from Individuals with Type 2 Diabetes Is Associated with Reduced Glucose-Stimulated Insulin Secretion. Diabetologia, 57, 122-128. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Xia, T., Liao, Q., Jiang, X., Shao, Y., Xiao, B., Xi, Y., et al. (2014) Long Noncoding RNA Associated-Competing Endogenous RNAs in Gastric Cancer. Scientific Reports, 4, Article No. 6088. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Varghese, V.K., Shukla, V., Kabekkodu, S.P., Pandey, D. and Satyamoorthy, K. (2017) DNA Methylation Regulated MicroRNAs in Human Cervical Cancer. Molecular Carcinogenesis, 57, 370-382. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Yang, X., Wu, M., Kong, X., Wang, Y., Hu, C., Zhu, D., et al. (2024) Exosomal miR-3174 Induced by Hypoxia Promotes Angiogenesis and Metastasis of Hepatocellular Carcinoma by Inhibiting HIPK3. iScience, 27, Article ID: 108955. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Ji, L., Chen, W., Fan, X., Zhou, F., Deng, X. and Gu, J. (2020) Overexpression of lincRNA02471 Promote Cancer Development though miR-758/HIPK3 Signaling Pathway in Papillary Thyroid Cancer. American Journal of Translational Research, 12, 531-540.
|
|
[23]
|
Tao, L., Xu, C., Shen, W., Tan, J., Li, L., Fan, M., et al. (2022) HIPK3 Inhibition by Exosomal Hsa-miR-101-3p Is Related to Metabolic Reprogramming in Colorectal Cancer. Frontiers in Oncology, 11, Article ID: 758336. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Hu, Y., Guo, F., Zhu, H., Tan, X., Zhu, X., Liu, X., et al. (2020) Circular RNA-0001283 Suppresses Breast Cancer Proliferation and Invasion via miR-187/HIPK3 Axis. Medical Science Monitor, 26, e921502. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Li, Z., Lin, C., Zhao, L., Zhou, L., Pan, X., Quan, J., et al. (2018) Oncogene miR-187-5p Is Associated with Cellular Proliferation, Migration, Invasion, Apoptosis and an Increased Risk of Recurrence in Bladder Cancer. Biomedicine & Pharmacotherapy, 105, 461-469. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Wu, Q., Qi, J., Liu, Z., Luo, X., Yu, K., Lu, Y., et al. (2024) HIPK3 Maintains Sensitivity to Platinum Drugs and Prevents Disease Progression in Gastric Cancer. Cancer Letters, 584, Article ID: 216643. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Liu, Y., Qian, L., Yang, J., Huang, H., Feng, J., Li, X., et al. (2018) The Expression Level and Prognostic Value of HIPK3 among Non-Small-Cell Lung Cancer Patients in China. OncoTargets and Therapy, 11, 7459-7469. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Curtin, J.F. and Cotter, T.G. (2004) JNK Regulates HIPK3 Expression and Promotes Resistance to Fas-Mediated Apoptosis in DU 145 Prostate Carcinoma Cells. Journal of Biological Chemistry, 279, 17090-17100. [Google Scholar] [CrossRef] [PubMed]
|